Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAFV600E Mutation-Prevalent Population

Thyroid

Volumn 26, Issue 7, 2016, Pages 901-910

  Lee, Seung Eun ^a   Hwang, Tae Sook ^a   Choi, Yoon La ^b   Han, Hye Seung ^a   Kim, Wan Seop ^a   Jang, Min Hye ^a   Kim, Suk Kyeong ^a   Yang, Jung Hyun ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; TELOMERASE REVERSE TRANSCRIPTASE; BRAF PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; GENETICS; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PROGNOSIS; SOUTH KOREA; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; REPUBLIC OF KOREA; TELOMERASE; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EID: 84978375400     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0488     Document Type: Article

References (55)

1. Mazzaferri EL 1992 Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med 93:359-362.
2. Guth S, Theune U, Aberle J, Galach A, Bamberger CM 2009 Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 39:699-706.
3. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18:784-791.
4. Lee JH, Lee ES, Kim YS, Won NH, Chae YS 2006 BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38:201-204.
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 83:2638-2648.
6. Hay ID 1990 Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19:545-576.
7. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
8. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
9. Tuttle RM, Leboeuf R 2008 Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 37:419-435, ix-x.
10. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM 2013 Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid 23:1401-1407.
11. Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP 2013 The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23:683-694.
12. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA, Jr., Sigurdson AJ, Nikiforov YE 2014 The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 99:E276-285.
13. V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501.
14. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397.
15. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY 2004 Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45:818-821.
16. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63:588-593.
17. V600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65:660-666.
18. V600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17:118-125.
19. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F 2012 The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390-4398.
20. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773.
21. V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97:4559-4570.
22. V600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 97:E1745-1749.
23. V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine 45:462-468.
24. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97.
25. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL 2011 A highthroughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 17:2385-2394.
26. Eloy C, Santos J, Soares P, Sobrinho-Simoes M 2011 The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265-276.
27. V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36:844-850.
28. Hong AR, Lim JA, Kim TH, Choi HS, Yoo WS, Min HS, Won JK, Lee KE, Jung KC, Park do J, Park YJ 2014 The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades. Endocrinol Metab (Seoul) 29:505-513.
29. V600E mutation in multifocal papillary thyroid carcinoma in Korea. Surgery 155:689-695.
30. V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670.
31. Kim KH, Suh KS, Kang DW, Kang DY 2005 Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 55:540-545.
32. V600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 39:198-203.
33. Min HS, Choe G, Kim SW, Park YJ, Park do J, Youn YK, Park SH, Cho BY, Park SY 2008 S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol 21:748-755.
34. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-1566.
35. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M 2013 Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20:603-610.
36. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Maximo V, Sobrinho-Simoes M, Soares P 2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99:E754-765.
37. V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32:2718-2726.
38. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V 2015 TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol 172:403-413.
39. de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei G, Durante C, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G, Ciarrocchi A 2015 TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid 25:1013-1019.
40. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D 2014 The age and shorter telomeredependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33:4978-4984.
41. Shay JW, Bacchetti S 1997 A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791.
42. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R 2013 TERT promoter mutations in familial and sporadic melanoma. Science 339:959-961.
43. Quaas A, Oldopp T, Tharun L, Klingenfeld C, Krech T, Sauter G, Grob TJ 2014 Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch 465:673-677.
44. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R 2013 TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 110:17426-17431.
45. Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R 2015 TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17:45-52.
46. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-959.
47. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, Wiencke JK, Wrensch MR, Chang SM, Walsh KM, Myong S, Song JS, Costello JF 2015 Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348:1036-1039.
48. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N 2009 (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 106:4519-4524.
49. Moreno Egea A, Rodriguez Gonzalez JM, Sola Perez J, Soria Cogollos T, Parrilla Paricio P 1993 Prognostic value of the tall cell variety of papillary cancer of the thyroid. Eur J Surg Oncol 19:517-521.
50. Ostrowski ML, Merino MJ 1996 Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964-974.
51. Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, Perren A 2015 Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer 22:419-429.
52. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Hoog A, Larsson C, Xu D 2014 TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 120:2965-2979.
53. Liu R, Xing M 2014 Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer 21:825-830.
54. Holler T, Theriault J, Payne RJ, Clark J, Eski S, Freeman JL 2009 Prognostic factors in patientswithmultiple recurrences of well-differentiated thyroid carcinoma. J Oncol 2009:650340.
55. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L 2016 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1-133.